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Rapport de synthèse: Prevalence, awareness and treatment of type 2 diabetes 
mellitus in Switzerland. The COLAUS study 
Le diabète de type 2 (DT2) a une prévalence élevée dans les pays industrialisés, et on s'attend 
à une augmentation dans les années à venir en raison du vieillissement de la population ainsi 
que des modifications du mode de vie. Il existe malheureusement peu de données 
épidémiologiques sur la prévalence et la prise en charge du diabète en Suisse. Les objectifs de 
cette étude étaient donc 1) évaluer la prévalence du DT2 dans une cohorte lausannoise; 2) 
caractériser la prise en charge des patients atteints de DT2, et 3) identifier les facteurs associés 
à la prévalence, la connaissance par les patients de leur maladie et le traitement du DT2. 
Pour ce faire, 6181 sujets (3246 femmes), âgés de 35 à 75 ans et vivant à Lausanne ont été 
inclus dans l'étude. La prévalence totale du DT2 était de 6.3% (intervalle de confiance à 95%: 
5. 7-7 .0% ), une valeur comparable à celle des pays avoisinants. La prévalence était plus élevée 
chez les hommes que chez les femmes (9.1% contre 3.8%, p<0.001), et augmentait avec 
l'âge. Deux tiers des patients avec DT2 (65.3%; 60.4-70.0%) avaient connaissance de leur 
situation, et plus de trois-quarts d'entre eux étaient traités. Les hommes étaient plus 
fréquemment traités que les femmes (91.3% contre 75.9%, p<0.001). La plupart des patients 
suivait une monothérapie (majoritairement par biguanides). Parmi les sujets avec une thérapie 
multiple, une prévalence plus élevée de glycémie à jeun ??:.7 mmol/l était présente. L'analyse 
multivariée a montré que le sexe masculin, l'âge croissant et un indice de masse corporelle 
élevé étaient associés à une plus grande prévalence du DT2, alors qu'aucune association n'a 
été trouvée pour l'activité physique et la consommation d'alcool. Parmi les sujets atteints de 
DT2, l'âge croissant était positivement associé à la connaissance du diabète, de même que 
l'âge croissant et le sexe masculin étaient associés à une plus grande prévalence du traitement. 
Le faible taux de connaissance de diabète pourrait être dû à un manque de dépistage par les 
médecins de premier recours. La présence d'autres facteurs de risque cardiovasculaire devrait 
inciter les médecins à un dépistage du diabète pour obtenir un meilleur profil de risque. 
Cette étude a des limitations. D'abord, aucune mesure de l'hémoglobine glyquée n'a été 
mesurée, et par conséquent la détermination de la prise en charge uniquement par la glycémie 
à jeun peut être difficile. Ensuite, le taux de participation était bas et pourrait limiter 
l'interprétation des résultats ; néanmoins, il est comparable à celui d'autres études effectuées 
dans les pays occidentaux. Il existe peu de données épidémiologiques du DT2 en Suisse, 
cette étude permet donc d'évaluer la situation actuelle et de déterminer la prévalence et la 
prise en charge du diabète à Lausanne à travers la cohorte CoLaus. Une telle étude a par 
conséquent son importance dans le contexte actuel, au vu du vieillissement de la population et 
de l'augmentation des facteurs de risque cardio-vasculaires. 
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Abstract 
Ahns To assess the prevalence, awareness and treatment levels of Type 2 diabetes in a Swiss city. 
Methods Population-based cross-sectional study of 6181 subjects (3246 women) aged 35-75 years living in 
Lausanne, Switzerland. Type 2 diabetes was defined as fasting plasma glucose ;:: 7 mmol/l and/or oral hypoglycaemic 
treatment and/or insulin. 
Results Total prevalence of Type 2 diabetes was 6.3% (95% confidence interval: 5.7-7.0%), higher in men (9.1 %) 
than in women (3.8%, P < 0.001) and increased with age. Two-thirds (65.3%; 60.4-70.0%) of participants with Type 2 
diabetes were aware of their status and among those aware 86.0% (81.5-90.3%) were treated. Treatment was more 
frequent in men (91.3%) than in women (75.9%, P < 0.001). Two-thirds of those treated for Type 2 diabetes were on 
monotherapy. Biguanides were prescribed in 65.0% of Type 2 diabetes patients and represented 48% of ail antidiabetic 
drugs. Multivariable analysis showed male gender, increasing age, waist or BMI to be positively associated with 
prevalence of Type 2 diabetes, while leisure-time physical activity and alcohol consumption were negatively associated. 
Among participants presenting with Type 2 diabetes, increasing age was positively associated with awareness of Type 2 
diabetes. Among subjects diagnosed with Type 2 diabetes, male gender and increasing age were positively associated 
with treatment. 
Conclusion Prevalence of Type 2 diabetes in Switzerland is estimated to be between 5.7% and 7.0%. Two-thirds of 
patients with Type 2 diabetes are aware of their status, and over three quarters of those aware are treated. 
Keywords: cross-sectional study, epidemiology, prevalence; treatment, Type 2 diabetes, Switzerland. 
This is an Accepted Article that has been peer-reviewed and approved for publication in the 
Diabetic Medicine, but has yet to undergo copy-editing and proof correction. Please cite this article 
as an "Accepted Article"; doi: 10.111 l/j.1464-5491.2011.03422.x 
Introduction 
Type 2 diabetes has a relatively high prevalence in industrialized countries [11 and it is expected that between 2010 and 
2030 there will be a 69% increase in the number of adults with diabetes in developing countries and a 20% increase in 
developed countties [2]. This increase will be mainly caused by ageing of the population and lifestyle changes (Jack of 
physical activity, modifications of eating habits, etc.) [3], making Type 2 diabetes an important public health problem. 
Severa! studies have shown that management of diabetes is far from optimal [ 4-6], with a sizable proportion of treated 
diabetic subjects not achieving adequate glucose levels. Further, little if no epidemiological data are available regarding 
prevalence and management of diabetes and Type 2 diabetes in Switzerland. A study conducted among patients from 
medical practitioners led to a prevalence estimation of 10% [7] but no specific diagnostic criteria were defined. Another 
study conducted in a random sample of the Geneva population reported a prevalence of self-reported antidiabetic 
treatment of 5% in men and Jess than 2% in women [8], but no prevalence data was available. Hence, the objectives of 
this study were: ( 1) to assess the prevalence of Type 2 diabetes in a population-based study; (2) to characterize the 
management of Type 2 diabetes patients; and (3) to identify the factors associated with Type 2 diabetes prevalence, 
awareness and treatment. 
Materials and methods 
The CoLaus study 
The objectives and design of the CoLaus study have been described previously [9]. Briefly, the CoLaus Study was 
designed to investigate the prevalence and genetic detenninants of risk factors for cardiovascular disease. The survey 
started in 2003 and was approved by the Institutional Ethics Cmmnittee of the University of Lausanne (Switzerland). 
The target sample size was 6000 subjects. Ali subjects aged between 35 and 75 years living in Lausanne were identified 
from a city register, and a random sample of 19 830 subjects (35% of the overall population) was invited to participate 
by mail. Subjects who volunteered to participate were then contacted by phone within 14 c\ays by one of the staff 
members to set up an appointment. Subjects who c\id not answer were sent a second invitation letter. If no answer was 
obtainec\, they were contactec\ by telephone. Subjects were consic\erec\ as non-participants if they cleclined to participate 
and as non-responc\ers if contact coule\ not be made after two successive letters and three successive phone calls. 
lnc\ivic\uals who clic\ not live in Lausanne anymore, who were deac\ or who clic\ not meet the age criteria were consic\ered 
as non-eligible. Inclusion criteria also includec\ providing written informec\ consent and being of Caucasian origin. The 
latter inclusion criterion was chosen because of the genetic aspect of the study. Of the initial 19 830 subjects sampled, 
54 subjects were considered as non-eligible before contact and 15 109 (76%) responses were obtained. A total of 4667 
subjects die\ not respond. Among responders, 6189 (41%) subjects declinec\ to participate in the study and 799 (5%) 
were consic\erec\ as non-eligible. The sample of 8121 subjects who agreec\ to participate represented 41 % of the initially 
sampled population, 54% of all responders and 57% of ail eligible responders. As there were more eligible participants 
than requested for the initial study, the final 1383 subjects were not incluc\ed and die\ not attend the health exarnination. 
As the CoLaus stuc\y focused on the genetics of cardiovascular disease, it only incluc\ed subjects of Caucasian 01igin; 
hence, a further 549 non-Caucasian participants were also excluded after benefiting from the health examination. 
Finally one participant initially incluc\ec\ withc\rew from the stuc\y, thus leaving 6188 participants (participation rate 
41 % ). No data regarc\ing non-participants was available. Of the initial 6188 participants, seven were excluded because 
of missing information regarding glucose and diabetic status. 
Participants were asked to attend the outpatient clinic at the Centre Hospitalier Universitaire Vaudois (CHUV), 
Lausanne, in the morning after an overnight fast. Data were collected by trainec\ field interviewers during a single visit 
lasting about 60 min. Information on demographic data, socio-economic and maiital status, lifestyle factors, persona! 
and family history of c\isease and cardiovascular risk factors and treatment was collected. 
Anthropometric data 
Body weight and height were measured with patticipants standing without shoes in light indoor clothes. Body weight 
was measured in kilograms to the nearest 100 g using a Seca® scale, which was calibrated regularly. Height was 
measured to the nearest 5 mm using a Seca height gauge. Body mass index was calculatec\ as weight/height2• 
Overweight was c\efined as a BMI ~ 25 kg/m2 and< 30 kg/m2 ; obesity was defined as a BMI ~ 30 kg/m2• 
Waist was measured with a non-stretchable tape over the unclothed abdomen at the narrowest point between the 
lowest rib and the iliac crest. Two measures were made and the mean (expressed in centimetres) used for analyses. 
Abdominal obesity was considerec\ for a waist 2 102 cm for men and 2 88 cm for women. 
Biological analyses 
Most biological assays were performed by the CHUV Clinical Laboratory on fresh blood samples within 2 h of blood 
collection, and additional aliquots were stored at -80°C. Ail measurements were conducted in a Modular P apparatus 
(Roche Diagnostics, Switzerland). The following analytical procedures (with maximum inter-batch and intra-batch 
CVs) were used: total cholesterol was determined by CHOD-PAP (cholesterol oxidase--p-aminophenazone; Roche 
Diagnostics, Mannheim, Germany) (l.6%-1.7%); HDL-cholesterol was determined by CHOD-PAP + PEG 
(polyethylene glycol) + cyclodextrin (3.6%-0.9%); glucose was determined by glucose dehydrogenase (2.1 %-1.0% ). 
Dia be tes 
Diabetes was defined as fasting plasma glucose (FPG) ;::: 7 mmol/l flO] and/or presence of ornl hypoglycaemic 
treatment and/or insulin. In the current analyses, only subjects with Type 2 diabetes were included. Type 1 diabetes was 
defined by a positive answer to the question 'Do you have type 1 (juvenile) diabetes?'. Awareness of diabetes was 
defined as a positive answer to the question 'Have you ever been told by a doctor that you have diabetes?' Treated 
diabetic subjects were defined as those taking oral anti-diabetic drugs und/or insulin. Oral unti-diabetic drugs were 
assessed by systematically checking ail medicines taken and brought to the study site by the participants and 
categorized into insulin, biguanides and others (al! non-insulin, non-biguanide antidiabetic drugs such as 
sulphonamides, thiazolidinediones, a-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitors). Age at diagnosis of 
Type 2 diabetes was provided whenever possible; no selection was perforrned. 
Awareness of dyslipidaemia (respectively hypertension) was defined as a positive answer to the question 'Did a 
doctor ever tell you that you had high cholesterol (resp. high blood pressure) levels?'. Alcohol consumption was 
categorized in drinkers and non-drinkers. Smoking status was categorized into never, former and current smoker. 
Leisure-time physical activity was considered when the subject reported exercising at least 20 min once per week. 
Statistical analysis 
Statistical analyses were performed using STATA v.11.0 (Stata Corp, College Station, TX, USA) and SAS v9.2 (SAS lnc, 
Cary, NC, USA). Results were expressed as number of subjects and (percentage) or as mean ±standard deviation. For 
prevalence, awareness and treatment rates, exact binomial 95% confidence intervals were also estimated using the cii 
command of STATA. Statistical analysis was made by x2 for categorical variables and by Student's t-test, non-pararnetric 
Kruskall-Wallis test or ANOVA for continuons variables. Bivariable correlations between continuons variables were 
assessed using a Spearman correlation. The variables significantly and independently associated with prevalence, 
awareness and treatment were identified using forward stepwise logistic regression with a 0.10 significance level for 
removal from the mode! and a significance level of 0.05 for addition to the mode!; the results were expressed as Odds 
ratio (OR) and 95% confidence interval. The variables studied in the multivariable analysis were gender, education 
(four groups), age (four groups), BMI (normal, overweight, obese), abdominal obesity (yes/no), smoking status (never, 
former, current), physical activity (yes/no), alcohol drinker (yes/no), parental history of Type 2 diabetes (yes/no), 
awareness of hypertension (yes/no), systolic blood pressure (continuons), awareness of dyslipidaemia (yes/no), total 
cholesterol (continuons) and baseline cardiovascular disease (yes/no). For all statistical testing, we used two-sided 
hypothesis testing with an a level of 0.05. 
Results 
Prevalence, awareness, treatment and control of diabetes 
Of the 6181 participants, 14 (prevalence 0.2%) presented with Type 1 diabetes and 392 (prevalence 6.3%) presented 
with Type 2 diabetes. Prevalence, awareness and treatment of Type 2 diabetes for the overall sample and according to 
gender are summarized in Table 1. Approximately two-thirds of participants with Type 2 cliabetes were aware of their 
status; no difference was found between genders (between gender comparison: x2 test= 0.22, P = 0.65). Awareness of 
Type 2 diabetes was associated with higher treatment levels among men (between gender comparison: X2 test= 11.31, 
P < 0.001 ). Two-thircls of treated subjects were on monotherapy. B iguanides were the most frequent antidiabetic drug 
prescribed, either alone or in combination with other drugs; insulin was the least used drug (Table 2). 
Fasting plasma glucose levels were 5.55 ± 1.14 mmol/I (mean ± SD) in the overall sample, 8.29 ± 2.61 mmol/l in 
participants with Type 2 diabetes, 8.38 ± 2.84 ll'llnol/l among participants aware of having Type 2 diabetes and 
8.45 ± 2.79 mmol/I among treated Type 2 diabetes participants. 
ln 123 Type 2 diabetes patients, age at diagnosis was obtained and averaged 49 ± 13 years, with no differences 
between genders. Conversely, age at diagnosis was lower among patients with family history of diabetes (43 ± 13 vs 
53 ± 12 years for those with and without family history, respectively, P < 0.001). The duration of diabetes was also 
significantly longer among subjects treated with insulin (15.4 ± 10.8 vs 9.6 ± 10.5 years, Kruskal-Wallis test P < 0.005) 
and positively correlated with the number of antidiabetic drugs prescribed (Spearman r = 0.39, P < 0.001 ). 
Factors associated with prevalence, awareness, treatment and control of diabetes 
Participants with Type 2 diabetes were more frequently male, of lower educational level, had a lower frequency of 
moderate drinking and of leisure-time physical activity, were older and had a higher BMI than non-diabetic participants 
(Table 3). Participants with Type 2 diabetes presented more frequently with abdominal obesity and more frequently 
reported a family history of Type 2 diabetes (Table 3). Finally, women with Type 2 diabetes reported more frequently a 
persona! history of gestational diabetes than non-diabetic female participants (4% vs 1 %, P < 0.001). As Type 2 
diabetes is a strong determinant of cardiovascular diseases because of its association with cardiovascular risk factors, no 
correlation between the latter and diabetes was assessed. Multivariable logistic regression analysis showed male gender, 
increasing age and BMI, abdominal obesity and family history of Type 2 diabetes to be positively associated with the 
prevalence of Type 2 diabetes and leisure-time physical activity and alcohol consumption to be negatively associated 
with prevalence of Type 2 diabetes (Table 4 ). 
Among participants with diabetes, awareness of Type 2 diabetes was significantly associated with BMI category, 
alcohol consumption, leisure-time physical activity, awareness of hypertension and dyslipidaemia, and persona! history 
of cardiovascular disease upon bivariable analysis. Multivariable logistic regression analysis showed increasing age and 
BMI (overall P-value for trend < 0.05) to be positively associated with awareness of Type 2 diabetes and alcohol 
consumption and leisure-time physical activity to be negatively associated with awareness of Type 2 diabetes (Table 4). 
Among participants aware of presenting with Type 2 diabetes, bivariate analysis showed antidiabetic drug treatment 
to be significantly associated with gender and smoking status (not shown). Multivariable logistic regression analysis 
showed male gender and increasing age to be positively and significantly associated with antidiabetic drug treatment 
(Table 4). 
Finally, among participants treated for Type 2 diabetes, taking two or more antidiabetic drugs was significantly 
associated with higher fasting plasma glucose levels (41.5% vs 21.6% of multi-therapy among participants with fasting 
plasma glucose (FPG)::.:: 7 11111101/l and< 7 mmol/l, respectively, P < 0.005). 
Discussion 
There is little information regarding the prevalence and management of Type 2 diabetes in the Swiss population. Thus, 
our data thus provide important information for the Public Health management of Type 2 diabetes. Further, with the 
current increase in overweight and obesity observed in Switzerland [Il], it is likely that the prevalence of Type 2 
diabetes will increase in the future. 
Prevalence of Type 2 diabetes was 6.3%, with higher rates in men. Those values are comparable to those reported for 
Italy [4] or Germany [12], but higher than those reported in other Italian [13], French [14] or German [15] studies, 
although in the last two cases only self-reported prevalence of Type 2 diabetes was obtained. Nevertheless, the reported 
prevalence of Type 2 diabetes in our study was 4.2%, higher than in the two aforementioned studies [14,15]. The 
prevalence found in this study was lower than reported for Switzerland [7,16): a possible explanation is that both 
prevalence rates were estimated either among consulting patients [7] or using data from Germany, not from 
Switzerland. As there is no nationwide study assessing prevalence of diabetes using fasting plasma glucose, this study 
provides a first estimation of the prevalence of Type 2 diabetes in Switzerland using a population-based sample. 
Overall, our data indicate that the prevalence of Type 2 diabetes in Switzerland is comparable to neighbouring 
countries. 
Approximately two-thirds of subjects with Type 2 diabetes were aware of their status. A possible explanation for this 
rather low awareness rate might be a Jack of screening by prirnary care physicians, as bas been shown in other countries 
[17], although no information on screening procedures is currently available for Switzerland. Hence, it would be helpful 
to implement more thoroughly the World Health Organization or American Diabetes Association recommendations 
regarding Type 2 diabetes screening [18,19]. Indeed, early screening and management of Type 2 diabetes in the 
population aged over 45 years has shown to be cost effective [20], even among younger subjects [21]. 
Slightly less than nine out of 10 Type 2 diabetes aware patients were treated with antidiabetic drugs, a value 
comparable to that found in other studies conducted in Switzerland [7], the USA [6] or Germany [15] but higher than 
that found in a study conducted in Italy [4]. Almost two-thirds of treated Type 2 diabetes patients were on monotherapy, 
which is higher than reported for Italy (33%) [4] or Germany (40%) [22] but slightly lower or comparable to that 
reported for France (66-83%) [5,23]. Biguanides (metformin) represented 48% of all antidiabetic medicines prescribed 
and were prescribed to 65% of Type 2 diabetes patients, a value that is higher than in France [5,23], close to that for 
Germany [15] and lower than in Italy [4]. In addition, 19% of treated Type 2 diabetes patients received insulin 
treatment (alone or in combination), a value comparable to that for France [23-25], higher than that for Italy [4] and 
lower than that for Germany (22], although the subjects in the German and US studies with Type 1 diabetes were also 
included. Overall, our results suggest that antidiabetic drug treatment prescription habits in Switzerland resemble more 
closely those of France than of the other neighbouring countries, although some differences in the choice of oral 
antidiabetic drug were found. 
ln agreement with other studies [23,26,27], the prevalence of Type 2 diabetes increased with age, waist and BMI 
status. Similarly, subjects who were physically active had a lower risk of Type 2 diabetes, a finding also in agreement 
wi th the literature [3]. 
Contrary to some studies conducted in ltaly [30] or the USA [31], but in agreement with others [32], no differences 
were found between educational levels regarding Type 2 diabetes prevalence, awareness and treatment rates. Regarding 
awareness and treatment, the most likely explanation is the fact that, in Switzerland, health insurance is mandatory [33), 
and thus the lack of screening or treatment among uninsured subjects [34] is minimized. Nevertheless, other 
possibilities such as the lack of power because of a small sample size cannot be ruled out. Finally, the higher prevalence 
and awareness of Type 2 diabetes among elderly subjects or subjects with other comorbidities is in agreement with the 
literature [35,36] and is probably associated with a risk factor clustering or higher likelihood of being screened as a 
result of a greater number of consultations. Indeed, the presence of other cardiovascular Iisk factors might prompt 
medical practitioners to screen for diabetes in order to obtain a better cardiovascular risk profile of their patients. 
A higher prevalence of fasting plasma glucose levels 2: 7 mmol/l was found among subjects on multithernpy. 
Possible explanations include the fact that patients received more drug items because of previous poor glycaemic 
control, differential adherence to recommended standards of diabetes care by Swiss practitioners [38] or the fact that 
Type 2 diabetes patients tend to give glycaemic control a lower rating than their doctors [39]. Another explanation is 
that subjects on multithernpy have a disease that progresses over a long time and is more difficult to control even 
though they are on multidrug regimen (they have a longer history of diabetes) but further studies are needed to better 
assess this issue. 
The present study has some limitations. First, no measurement of HbAlc was performed. Bence, glycaemic control 
could be assessed only by fasting plasma glucose and comparison with data from the literature is difficult. Also, no 
data was available regarding antidiabetic posology or presence of dietary management. Nevertheless, our results 
indicate that a sizable fraction of patients with Type 2 diabetes present with high fasting plasma glucose values, 
stressing the need for a stronger Type 2 diabetes surveillance and increased patient motivation, as this leads to better 
glycaemic control and lower treatment costs [40]. The participation rate was also low (41 %), which might limit the 
generalization of our findings. Nevertheless, low participation rates are typical of surveys in Western countries and 
comparable with the MONICA surveys conducted in Switzerland and other countries [41]. Only subjects of Caucasian 
origin were included in this study, and whether the Lausanne population is representative of the whole country might be 
questionable. A considerable proportion of the Lausanne population is non-Swiss or cornes from other cantons: in 2006, 
out of the 128 231 Lausanne inhabitants, 49 330 (38%) were non-Swiss - 38 513 (30%) came from other cantons, and 
only 40 388 subjects (32%) were actually from the Vaud canton. Further, the prevalences of reported antidiabetic 
treatment in men and women are identical to the 2003 values reported in a study conducted in random samples of the 
Geneva population [8). It has also been shown that a single fasting plasma glucose measurement might overestimate the 
prevalence of diabetes [42], although the inverse result bas been found [43]. Yet, separate measurements of fasting 
plasma glucose would be difficult to perform in an epidemiological setting and, as there is currently no nationwide 
study assessing prevalence of diabetes using fasting plasma glucose, this study thus provides a first estimation of the 
prevalence of Type 2 diabetes in Switzerland using a population-based sample. Owing to its cross-sectional nature, this 
current study might not be able to assess the best correlates of Type 2 diabetes prevalence and control; the ongoing 
fo\low-up of the CoLaus cohort will provide more precise information on this topic. Also, the diagnosis of Type 1 
diabetes was based on persona! anamnesis and not on objective measurements of anti-GAD (glutamic acid 
decarboxylase) antibodies; however, tlùs methodology is not commonly used in epiclemiological practice. Finally, we 
have no information regarding non-responders; as the prevalence of diabetes might be higher among non-responders 
[22], our estimates might be underrated. 
In smmnary, our results indicate that the prevalence of Type 2 diabetes in Switzerland is estimated at between 5.7% 
and 7.0%. Although one-third of Type 2 diabetes patients are unaware of their status, most patients with Type 2 
diabetes are treated but control of glycaemia is low. 
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. Table 1. Prevalence, awareness and treatment of type 2 diabetes, overall and by gender 
Ali Women Men 
Ail subjects 6181 3246 2935 
Diabetes 392 (6.3) 124 (3.8) 268 (9.1) 
[5.7-7.0] [3.2-4.5] [8.1-10.2] 
Subjecls wilh diabetes 392 124 268 
Aware 256 (65.3) 83 (66.9) 173 (64.6) 
[60.4-70.0] [57.9-75.l] [58.5-70.3] 
Subjects aware of diabetes 256 83 173 
Treated 221 (86.3) 63 (75.9) 158 (91.3) 
[81.5-90.3] [65.3-84.6] [86.1-95.1] 
Subjects treated for diabetes 221 63 158 
Fasting plasma glucose< 7 mrnol/I 74 (33.5) 25 (39.7) 49 (31.0) 
Fasting plasma glucose 46 (20.8) 15 (23.8) 31 (19.6) 
< 6.5 11111101/I 
Results are expressed as number of subjects (percentage) and .exact binomial 95% confidence intervals are also provided (in square 
brackets) for prcvalence, treatment and control rates. 
Table 2. Antidiabetic treatment prescribed, overall and by gender, among subjects trcated for diabetes 
Ail (N= 221) Women (11 = 63) Men (11=158) 
Monotherapy (total) 144 (65.2) 44 (69.8) 100 (63.3) 
Insulin 20 (9.0) 8 (12.7) 12 (7.6) 
Biguanides 7.l (33.1) 24 (38.l) 49 (31.0) 
Other antidiabetics* 51 (23.1) 12 ( 19.1) 39 (24.7) 
Combined therapy (total) 77 (34.8) 19 (30.2) 58 (36.7) 
Insulin + biguanides 9 (4.0) 2 (3.2) 7 (4.4) 
Insulin + others 7 (3.2) l (1.6) 6 (3.8) 
Higuanides + others 55 (24.9) 12 (19.1) 43 (27.2) 
Insulin + biguanides + others 6 (2.7) 4 (6.4) 2 (1.3) 
Results are expressed as number of subjects and (percentage). *Except insulin and analogues. 
Table 3: Characteristics of subjects with Type 2 diabetes compared with subjects without diabetes 
Subjects with Type 2 Subjccts without p 
diabetes (11 = 392) diabetes (11 = 5789) 
Women (%) 124 (31.6) 3122 (53.9) <0.001 
Age ( years) 60.3 ± 8.7 52.6 ± I0.7 < 0.001 
Education(%) 
Basic 100 (25.5) 1190 (20.5) 
Apprenticeship 170 (43.4) 2112 (36.5) < 0.001 
High school/college 87 (22.2) 1382 (23.9) 
University 35 (8.9) 1105 (19.1) 
BMl(kg/m') 30.2 ± 5.4 25.5 ± 4.3 <0.001 
BMI categories (%) 
Normal 64 (16.3) 2905 (50.2) 
Overweight 133 (33.9) 2121 (36.6) < 0.001 
Obese 195 (49.7) 763 (13.2) 
Abdominal obesity (%) 251 (64.0) 1599 (27.6) <0.001 
Smoking stalus (%) 
Never 123 (31.4) 2355 (40.7) 
Fo1mer 171 (43.6) 1860 (32.1) <0.001 
Current 98 (25.0) 1574 (27.2) 
Alcohol drinking (%) 277 (70.7) 4232 (73.1) 0.29 
Physically active(%) 160 (40.8) 3270 (56.5) < 0.001 
Persona! hislory of(%) 
Cardiovascular disease 63 (16.1) 332 (5.7) <0.001 
Stroke 12 (3.1) 58 (1.00) < 0.001 
Myocardial infarction 17 (4.3) 83 (1.4) <0.001 
Peripheral arterial disease 25 (6.4) 136 (2.4) <0.001 
Parental history of(%) 
Cardiovascular disease 136 (34.7) 1871 (32.3) 0.33 
Myocardial infarction 92 (23.5) 1185 (20.5) 0.16 
Stroke 60 (15.3) 894 (15.4) 0.92 
Diabetes 126 (32.1) 1021 (17.6) < 0.001 
Menopause (%)' 108 (27.6) 1700 (29.4) 0.43 
Hypertension in pregnancy (%)' 4 (1.0) 114 (2.0) 0.18 
Diabetes in pregnancy (%)" 4 (1.0) 27 (0.5) 0.13 
Systolic blood pressure (mmHg) 139 ± 18 128 ± 18 < 0.001 
Diastolic blood pressure (mmHg) 83 ± 11 79 ± 11 < 0.001 
Total choleslerol (mmol/I) 5.45 ± 1.17 5.60 ± 1.03 < 0.01 
LOL choleslerol (mmol/l) 3.18 ± 1.01 3.35 ± 0.91 < 0.01 
HDL cholesterol (nunol/l) J.38 ± 0.36 1.65 ± 0.44 < 0.001 
Triglycerides (mmol/1)1 1.7 [1.2-2.6] 1.1 [0.8-1.6] < 0.001 
Results are expressed as number of subjects and (percentage), as mean ±standard deviation and as median and [interquartile range] 
(for triglycerides). •For women only. Statistical analysis by x2 for categorical variables and by Student's t-test or nonparametric 
Kruskall-Wallis test(§) for continuons variables. 
Table 4. Multivariable analysis of the factors associated with prevalence, awareness and treatment of Type 2 diabetes 
Prevalence (11 = 6181) Awareness (11 = 392) Treatment (11 = 256) 
Gender (man vs woman) 
Age group (years) 
35-44 
45-54 
55-64 
65-75 
BMI group 
3.01 (2.33-3.88) 
1 (ref.) 
2.32 (1.47-3.65) 
6.22 (4.07-9.51) 
8.20 (5.22-12.9) 
Normal 1 (ref.) 
Overweight 1.51 (J.07-2.12) 
Obese 5.14 (3.39-7.78) 
Abdominal obesity* 1.43 (1.04-1.96) 
Physical activity* 0.64 (0.51--0.80) 
Alcohol intake* 0.72 (0.56-0.93) 
Parental history of Type 2 diabetes* 2.47 (1.93-3.16) 
Baseline cardiovascular discase* 1.41 (1.02-1.96) 
1 (ref.) 
1.82 (0.71-4.64) 
2.60 ( 1.09-6. J 7) 
4.68 (1.87-11.7) 
1 (ref.) 
0.82 (0.44-1.56) 
1.55 (0.84-2.88) 
0.58 (0.37--0.91) 
0.39 (0.23-0.67) 
3.75 ( 1.74-8.05) 
1 (ref.) 
2.09 (0.52-8.34) 
3.02 (0.85-10.7) 
13.8 (2.95-64.2) 
Statistical analysis by forward stepwise logistic regression with a 0.10 significance level for removal from and a significance level of 
0.05 for addition to the mode!. The variables studied were gender, education (four groups), age (four groups), BMI (normal, 
overweight, obese), abdominal obesity (yes/no), smoking status (never, former, current), physical activity (yes/no), alcohol clrinkcr 
(yes/no), parental history of Type 2 diabetes (yes/no), awareness of hypertension (yes/no), systolic blood pressure (continuons), 
awareness of dyslipiclaemia (yes/no), total cholesterol (continuous) and baseline cardiovascular disease (yes/no). Results are 
expressed as Odds ratio and (95% confidence interval). *, Odds ratio calculated for presence vs absence of the condition; -, not 
retained in the mode!. 
